CNTB

$2.54+$0.21 (+9.01%)prev close

Compare

Held by

portfolios on TandT

Bookmarked by

users

Avg position size

—

of holders' portfolios

13F filers

institution

Market cap

$146.7M

63M shares

52-week range

$1.23 – $3.82

51% from low

Sector

PHARMACEUTICAL PREPARATIONS

Exchange

NASDAQ

Change$-19.20

Analyst estimates (consensus)

Year	Est. revenue	Growth	Est. EPS	EPS range	Fwd P/E	# Analysts
2026	$5M	+6650.4%	$-1.10	$-1.13–$-1.03	—	5
2027	$10M	+91.4%	$-0.94	$-1.30–$-0.60	—	6
2028	$17M	+75.7%	$-0.92	$-1.81–$-0.44	—	5
2029	$34M	+102.0%	$-0.72	$-1.93–$0.16	—	1

Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep

Earnings surprises

Beat consensus in 5 of the last 8 reported quarters

Reported	Est. EPS	Actual	Surprise
2026-08-12	$-0.31	$-0.27	+14.3%
2026-05-12	$-0.29	$-0.34	-17.2%
2026-03-31	$-0.30	$-0.27	+10.0%
2025-11-12	$-0.03	$-0.04	-29.7%
2025-08-13	$-0.22	$-0.03	+85.4%
2025-05-15	$-0.26	$-0.03	+89.9%
2025-03-31	$-0.05	$-0.06	-13.7%
2024-09-05	$-0.03

DCF fair valuemodel estimate

Intrinsic value

$0.65

Price

$2.54

Implied downside

-74%

Peer comparison

Symbol	Price	Today	Mkt cap	P/E
CNTBConnect Biopharma Holdings Limited	$2.49	+6.91%	$157M	—
ARTVArtiva Biotherapeutics, Inc.	$11.48	-0.43%	$561M	—
CNTXContext Therapeutics Inc.	$0.50	+6.41%	$46M	—
IFRXInflaRx N.V.	$2.00	-0.25%	$295M	—
IMAImageneBio Inc	$5.74	-4.17%

Connect Biopharma Holdings Limited Ordinary Shares

Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.

www.connectbiopharm.com

Employees: 64
IPO / List date: Sep 3, 2025
HQ: SAN DIEGO, CA

Held by traders on TradeandTell

No one on the platform currently holds CNTB.

Super investors & insiders

Institutions holding (13F)

Institution	Shares	Reported
Renaissance Technologiesas of 2026-03-31	120,700	$316.2K

Insider activity (SEC Form 4)

Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.

Insider activity (SEC Form 4)

Recent trades on TradeandTell

No one on the platform has traded CNTB yet.

$CNTB chatter on StockTwits

J@Biotech80Bullish5h
$CURI Taken 51% profit Nice week 🤑🤑🤑🤑 Into $ANNX once l feel it’s the correct entry may add more to $CNTB before aseptember data let’s see Monday 🤑
View on StockTwits ↗
Teshuvah@TeshuvahBullish13h
@san_houston probably because $CNTB is the greatest stock in stock history
View on StockTwits ↗
mikey@mikeywoBullish16h
$CNTB can we please just say goodbye to the 2’s ? Idc if we sit in the 3’s the rest of this year but I’m tired of the 2’s.
View on StockTwits ↗
ravksin@san_houston20h
$CNTB why the uptick?
View on StockTwits ↗
mikey@mikeywoBullish22h
$CNTB
View on StockTwits ↗
From Lambo to Skoda@BennyBoy1822h
$CNTB sold , hopefully enter at lower position. Will off myself if they actually suceed and it blasts past $5 lol
View on StockTwits ↗
Evan@buythedipsisayBullish1d
$CNTB
View on StockTwits ↗
Fred Garcia@Maissessap1d
$CNTB All is well except that they need money, lots of it, to fund next P3. Current shareholders will be diluted hard. Barry Quart has a history to burn money full hands. Look at its former company: HRTX
View on StockTwits ↗
Teshuvah@TeshuvahBullish1d
$CNTB https://www.globenewswire.com/news-release/2026/08/12/3344061/0/en/connect-biopharma-reports-second-quarter-2026-financial-results-and-provides-business-update.html
View on StockTwits ↗
Evan@buythedipsisayBullish3d
$CNTB Connect quietly registered another Phase 2 rademikibart study. NCT07705737, a 40-patient, open-label Phase 2 trial testing a single 300 mg IV dose of rademikibart in patients arriving for urgent treatment of an acute asthma or COPD exacerbation. The primary endpoint is change in FEV1 at one week; the study was registered in July and lists completion around December 2026. CNTB already knows the blinded Seabreeze results only to the extent permitted before database lock/unblinding - but this is still bullish imo. They are spending money and operational bandwidth before the Seabreeze readouts to expand the exact acute-exacerbation concept they’re betting the company on. And they’re specifically testing the IV formulation that previously produced very rapid lung-function improvement.
View on StockTwits ↗
From Lambo to Skoda@BennyBoy183d
$CNTB september soon , getting nervous
View on StockTwits ↗
mikey@mikeywo3d
$CNTB Barry is there a Q2 webcast in our future ? Not withstanding this piss poor CEO we are lucky this hasn’t bled down to 1.50$. Nothing moves money burning bios but news and apparently Barry has nothing to say.
View on StockTwits ↗
Teshuvah@TeshuvahBullish6d
$CNTB is love $CNTB is life
View on StockTwits ↗
Shahid Attar@shahidattarBearish6d
$CNTB Can you break below 2.05 next week?
View on StockTwits ↗
elmono@elmonoBearishAug 5
$CNTB refuses to go up on a stellar biotech market. I think they are going to punish this ticker so hard on meh data. Easy -70% on that day in Sept 🤷‍♂️😏…..all the SLs of scared retail bunnies will be pulled….
View on StockTwits ↗

Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.